> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/thiamine-transporters.md).

# thiamine transporters

{% hint style="info" %}
**Section:** Complete Biochemistry → Transporters & Absorption\
**Reading level:** Plain-language summary first, then technical detail\
**Last reviewed:** October 2026 · **Evidence status:** Well established (molecular biology, genetics); mixed (drug interactions in humans)
{% endhint %}

## Summary

Thiamine (vitamin B1) carries a permanent positive charge at body pH, so at the low concentrations found in food it cannot pass freely through cell membranes. It relies on dedicated carrier proteins. The two main ones are **THTR-1**, encoded by the gene *SLC19A2*, and **THTR-2**, encoded by *SLC19A3*. They are responsible for absorbing thiamine from the gut, reabsorbing it in the kidney, and delivering it into tissues such as the brain, pancreas and bone marrow.

Once inside the cell, thiamine is converted to its active form, thiamine pyrophosphate (TPP), and a separate carrier moves TPP into mitochondria. Inherited faults in any of these steps cause distinct, recognisable diseases, several of which respond to high-dose thiamine. Some medicines also block these transporters, which is an active area of research.

## Key facts

|                             | THTR-1                                                                                   | THTR-2                                                      |
| --------------------------- | ---------------------------------------------------------------------------------------- | ----------------------------------------------------------- |
| **Gene**                    | *SLC19A2*                                                                                | *SLC19A3*                                                   |
| **Affinity for thiamine**   | Lower (low micromolar range)                                                             | Higher (nanomolar range)                                    |
| **Main locations**          | Widespread; intestine (apical and basolateral), kidney, pancreas, bone marrow, inner ear | Intestine (mainly apical), kidney, brain, placenta          |
| **Sodium-dependent?**       | No                                                                                       | No                                                          |
| **Disease when mutated**    | Thiamine-responsive megaloblastic anaemia (TRMA, Rogers syndrome)                        | Biotin–thiamine-responsive basal ganglia disease (BTBGD)    |
| **Known drug interactions** | Limited data                                                                             | Inhibited by fedratinib, metformin, trimethoprim (in vitro) |

## Plain-language explanation

{% tabs %}
{% tab title="For general readers" %}
Think of a cell as a building with locked doors. Thiamine is too "charged" to slip through the walls, so it needs a key-card door. THTR-1 and THTR-2 are two such doors.

* **In the gut**, these doors let thiamine from food into the lining of the intestine and then out the other side into the blood.
* **In the kidneys**, they pull thiamine back out of urine so it is not wasted.
* **In the brain and other organs**, they let thiamine into the cells that need it.

Having two different doors gives backup. Most tissues have both, so if one is faulty the other partly compensates. Problems show up most clearly in tissues that depend heavily on just one of them.

When very large amounts of thiamine are taken (well above dietary levels), some thiamine also leaks through the walls by simple diffusion, which helps explain why high doses can work around a faulty transporter in some genetic conditions.
{% endtab %}

{% tab title="For professionals" %}
THTR-1 and THTR-2 belong to the SLC19 solute carrier family, which also includes SLC19A1, the reduced folate carrier (RFC). Despite sequence similarity, RFC does not transport free thiamine, although it has been reported to carry phosphorylated thiamine (TMP/TPP).

Both THTRs mediate Na⁺-independent, pH-sensitive uptake of free thiamine, generally described as thiamine/H⁺ exchange. They differ mainly in affinity and tissue distribution: THTR-2 has substantially higher affinity, making it the dominant route at low luminal or extracellular concentrations.

Intracellularly, thiamine is phosphorylated by thiamine pyrophosphokinase (TPK1) to TPP, which effectively traps it in the cytosol. TPP is imported into mitochondria by the mitochondrial TPP carrier (SLC25A19), where it serves as a cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase and branched-chain α-ketoacid dehydrogenase.
{% endtab %}
{% endtabs %}

## Detailed biochemistry

### Intestinal absorption

Absorption takes place mainly in the small intestine (proximal jejunum predominantly) and follows **two kinetic regimes**:

{% stepper %}
{% step %}

#### Carrier-mediated (saturable)

Dominant at dietary concentrations. Dietary TPP is first dephosphorylated to free thiamine by intestinal phosphatases, then taken up across the apical membrane by THTR-2 and THTR-1.
{% endstep %}

{% step %}

#### Passive diffusion (non-saturable)

Becomes significant at pharmacological luminal concentrations. This is the basis for high-dose oral thiamine being able to partly bypass impaired transport.
{% endstep %}
{% endstepper %}

THTR-1 is found on both the apical and basolateral membranes of enterocytes, while THTR-2 is concentrated apically. Exit across the basolateral membrane into blood is therefore thought to depend largely on THTR-1.

Intestinal uptake is **adaptively regulated**: in thiamine deficiency, expression of the transporters (particularly THTR-2) increases. See [GI Factors Affecting Thiamine Uptake](broken://pages/fa7b936a5a5b06d4438d7966f1ad6f33c65df7e7) and [Mechanisms of Malabsorption](broken://pages/2a0d5d46380717fcf2639e31a45f31d244f053a8).

### Colonic uptake of microbial thiamine

Gut bacteria synthesise thiamine, much of it as TPP. Colonocytes express a dedicated **TPP transporter, SLC44A4 (TPPT)**, in addition to THTR-1/2. The contribution of microbial thiamine to whole-body status in humans is not quantified and remains an open question.

### Hepatic uptake

**OCT1 (SLC22A1)**, an organic cation transporter abundant in liver, transports thiamine with high capacity. Mouse studies link OCT1-mediated hepatic thiamine uptake to lipid metabolism and hepatic steatosis. The relevance to human fatty liver disease has not been established.

### Kidney

Thiamine is filtered at the glomerulus and reabsorbed in the proximal tubule via THTR-1 and THTR-2. When plasma thiamine exceeds the capacity for reabsorption, the excess is excreted in urine. This is why urinary thiamine rises steeply after high doses.

### Brain

Thiamine crosses the blood–brain barrier by carrier-mediated transport at physiological concentrations. The severe neurological picture of BTBGD (see below) indicates that THTR-2 is particularly important for the brain, though the exact cell types and directionality involved are still being studied.

### Mitochondrial import

| Protein                    | Gene       | Role                                   |
| -------------------------- | ---------- | -------------------------------------- |
| Thiamine pyrophosphokinase | *TPK1*     | Converts thiamine → TPP in the cytosol |
| Mitochondrial TPP carrier  | *SLC25A19* | Imports TPP into mitochondria          |

## Genetic disorders of thiamine transport and metabolism

These are grouped in OMIM as **thiamine metabolism dysfunction syndromes (THMD 1–5)**.

| Disorder                                                | Gene       | Core features                                                                                                                                                  | Response to thiamine                                                                                             |
| ------------------------------------------------------- | ---------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------- |
| **TRMA / Rogers syndrome** (THMD1)                      | *SLC19A2*  | Megaloblastic anaemia, diabetes mellitus, sensorineural hearing loss                                                                                           | Anaemia usually responds to pharmacological doses; diabetes may improve; hearing loss generally does not reverse |
| **BTBGD** (THMD2)                                       | *SLC19A3*  | Episodic subacute encephalopathy (confusion, dystonia, dysarthria), often triggered by fever; basal ganglia lesions on MRI; Leigh-like presentation in infants | Early biotin + thiamine can be strongly beneficial; delayed treatment may leave permanent deficits               |
| **Amish lethal microcephaly** (THMD3)                   | *SLC25A19* | Severe congenital microcephaly, α-ketoglutaric aciduria                                                                                                        | Not thiamine-responsive                                                                                          |
| **Bilateral striatal necrosis with neuropathy** (THMD4) | *SLC25A19* | Episodic encephalopathy, striatal necrosis, progressive polyneuropathy                                                                                         | Reported responses to thiamine in some cases                                                                     |
| **Episodic encephalopathy** (THMD5)                     | *TPK1*     | Episodic ataxia/encephalopathy, often with lactic acidosis                                                                                                     | Variable; thiamine used therapeutically                                                                          |

{% hint style="warning" %}
**Why does TRMA mainly affect blood, pancreas and inner ear?**\
The leading explanation is that these cells rely more heavily on THTR-1, with less compensation from THTR-2. This is supported by expression data but is not fully proven for every tissue.
{% endhint %}

<details>

<summary>Why biotin in BTBGD? (evidence note)</summary>

BTBGD was originally named for its response to biotin, but subsequent case series suggest thiamine is the more important component of treatment. How biotin contributes is not established; proposed explanations include effects on *SLC19A3* expression. Most evidence comes from case series rather than controlled trials, which is expected for a rare disease.

</details>

## Acquired transporter impairment

### Medications

| Drug                            | Evidence                                                                 | Notes                                                                                                                                       |
| ------------------------------- | ------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------- |
| **Fedratinib** (JAK2 inhibitor) | In vitro inhibition of THTR-2; clinical cases of Wernicke encephalopathy | Carries a regulatory warning for encephalopathy; thiamine monitoring is recommended. THTR-2 inhibition is a proposed, not proven, mechanism |
| **Metformin**                   | In vitro substrate and inhibitor of THTR-2; also an OCT1 substrate       | Clinical significance for thiamine status in people taking metformin is debated                                                             |
| **Trimethoprim**                | In vitro inhibition of thiamine transporters                             | Clinical relevance at standard doses is unclear                                                                                             |

### Alcohol

Chronic alcohol exposure reduces thiamine uptake in intestinal and renal models, partly by lowering THTR-1 and THTR-2 expression. This adds to poor intake and impaired phosphorylation as a cause of deficiency in alcohol use disorder.

### Other

Conditions that damage the small-intestinal lining (e.g., inflammatory bowel disease, after bariatric surgery) can plausibly reduce transporter-mediated uptake. Direct measurement of transporter expression in these conditions in humans is limited.

## Lipid-soluble derivatives and "transporter bypass"

Several synthetic derivatives were developed to improve absorption by avoiding reliance on THTR-1/2.

| Class              | Examples                           | How it enters cells                                                                                     | What is known                                                                                                     |
| ------------------ | ---------------------------------- | ------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------- |
| Disulfides         | TTFD (fursultiamine), sulbutiamine | Lipophilic; diffuse across membranes, then reduced to thiamine inside cells                             | Raise blood thiamine more than equivalent oral thiamine salts; brain penetration shown for some in animal studies |
| S-acyl derivatives | Benfotiamine                       | Dephosphorylated in gut to S-benzoylthiamine, absorbed, converted to thiamine mainly in blood and liver | Raises blood thiamine and TPP efficiently; animal data suggest limited increase in brain TPP                      |
| O-acyl derivatives | Dibenzoylthiamine (DBT)            | Lipophilic; converted to thiamine in tissues                                                            | Mostly preclinical data                                                                                           |

See [Thiamine Derivatives](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d) for full detail.

## Open questions and areas of uncertainty

* The proportion of whole-body thiamine supplied by gut bacteria in humans.
* Whether common genetic variants in *SLC19A2* or *SLC19A3* (not disease-causing mutations) meaningfully affect thiamine status in the general population.
* Whether long-term metformin use causes clinically relevant thiamine depletion.
* The precise transport routes into and out of neurons and glial cells.
* How biotin works in BTBGD.

## Evidence quality

| Claim type                                           | Strength                                                                      |
| ---------------------------------------------------- | ----------------------------------------------------------------------------- |
| Gene identity, protein function, tissue distribution | **Strong** — replicated across cell, animal and human genetic studies         |
| Genetic disease descriptions                         | **Strong** for diagnosis; **moderate** for treatment (case series)            |
| Drug interactions                                    | **Strong** in vitro; **limited** clinical evidence                            |
| Bypass by lipophilic derivatives                     | **Moderate** for blood levels; **limited** for brain/tissue effects in humans |

## Related pages

* [TPP Synthesis](broken://pages/952746c8c01357a3499328e00a07994a73144702)
* [Mechanisms of Malabsorption](broken://pages/2a0d5d46380717fcf2639e31a45f31d244f053a8)
* [GI Factors Affecting Thiamine Uptake](broken://pages/fa7b936a5a5b06d4438d7966f1ad6f33c65df7e7)
* [Thiamine Derivatives](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d)
* [Causes of Deficiency](broken://pages/e2f0079872756b16d945a693f3b5e16abb5efad9)
* [Medications That Deplete Thiamine](broken://pages/00d718dbc3f32e5ab225bfdf015ff8b19d175a99)
* [Wernicke Encephalopathy](broken://pages/0df4e5640d2cddb1b5382d5bf988f1b3acf84ddb)
* [Glossary: SLC, Km, apical, basolateral](broken://pages/c79ce1ed6f922bd2a91dc0d0f9972fc15d466888)

## References

1. Labay V, et al. Mutations in *SLC19A2* cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. *Nature Genetics*. 1999;22:300–304.
2. Fleming JC, et al. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. *Nature Genetics*. 1999;22:305–308.
3. Diaz GA, et al. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. *Nature Genetics*. 1999;22:309–312.
4. Zeng WQ, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in *SLC19A3*. *American Journal of Human Genetics*. 2005;77:16–26.
5. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. *Biochemical Journal*. 2011;437:357–372.
6. Nabokina SM, et al. Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. *Journal of Biological Chemistry*. 2014;289:4405–4416.
7. Chen L, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. *PNAS*. 2014;111:9983–9988.
8. Liang X, et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). *Molecular Pharmaceutics*. 2015;12:4301–4310.
9. Zhang Q, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. *Drug Metabolism and Disposition*. 2014;42:1656–1662.
10. Giacomini MM, et al. Interaction of 2,4-diaminopyrimidine-containing drugs including fedratinib and trimethoprim with thiamine transporters. *Drug Metabolism and Disposition*. 2017;45:76–85.
11. Rosenberg MJ, et al. Mutant deoxynucleotide carrier is associated with congenital microcephaly. *Nature Genetics*. 2002;32:175–178.
12. Spiegel R, et al. *SLC25A19* mutation as a cause of neuropathy and bilateral striatal necrosis. *Annals of Neurology*. 2009;66:419–424.
13. Mayr JA, et al. Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway. *American Journal of Human Genetics*. 2011;89:806–812.
14. Tabarki B, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. *Neurology*. 2013;80:261–267.
15. Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. *BMC Pharmacology*. 2008;8:10.
16. Reidling JC, Said HM. Adaptive regulation of intestinal thiamin uptake: molecular mechanism using wild-type and transgenic mice carrying hTHTR-1 and -2 promoters. *American Journal of Physiology: Gastrointestinal and Liver Physiology*. 2005;288(6):G1127–G1134.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
